#USA #Chicago #Pulmonary Fibrosis #Interstitial Lung Disease #PFF Registry

PFF Community Registry Hits 3,000 Participant Milestone

The Pulmonary Fibrosis Foundation (PFF) has announced a significant achievement—the enrollment of over 3,000 individuals in its Community Registry. This pivotal milestone marks not only an increase in participation but also a vital step forward in the understanding and treatment of pulmonary fibrosis (PF) and interstitial lung disease (ILD), severe conditions that collectively affect more than a quarter of a million individuals across the United States.

Empowering Research with Valuable Data

Launched in 2022, the PFF Community Registry has been a transformative tool in gathering data to expedite research initiatives that focus on developing improved treatments and potential cures for PF and ILD. The influx of participant data serves as a crucial resource for researchers who are dedicated to exploring the intricacies of these complex diseases. This growing database enhances the breadth and depth of research findings, enabling a more profound understanding of the characteristics and progression of PF and ILD.

As of now, the registry boasts over 2,000 patients currently living with pulmonary fibrosis and has facilitated 14 additional research projects, significantly influencing the scientific community's ability to innovate treatment methodologies. One notable project conducted by Dr. Lanier O'Hare centered on the often-overlooked experiences of caregivers. This study revealed that caregivers typically manage six different types of care each week, dedicating an average of 39 hours to their responsibilities. Notably, the median age of caregivers was found to be 63, several of whom still maintain employment while navigating these challenges. Intriguingly, only 22% of caregivers reported attending support groups, emphasizing a potential area for increased outreach and support.

Commitment to Growth and Research

Jessica Shore, PhD, RN, the Chief Scientific Officer of the Pulmonary Fibrosis Foundation, expressed gratitude for the community's involvement: "We appreciate all those in the pulmonary fibrosis community who have enrolled in the PFF Community Registry. Each experience shared adds to the strength of our research efforts, and our goal is to expand the registry to 6,000 participants by 2030."

In line with this commitment, the PFF has also strengthened its leadership by appointing Dr. Teja Kulkarni as Senior Medical Advisor for the registry. Dr. Kulkarni holds the position of Associate Professor of Pulmonology at the University of Alabama at Birmingham and brings vast experience in clinical care and research to the PFF. Her work emphasizes identifying imaging and clinical biomarkers that can predict disease progression more accurately, thus supporting clinical trials focused on new therapeutic options for ILD.

Diverse Voices Contributing to a Cure

The PFF Community Registry is designed to include participants from various backgrounds who are affected by PF and ILD. Eligible individuals include:

• - Patients diagnosed with pulmonary fibrosis or interstitial lung disease.
• - Lung transplant recipients who have a history of PF or ILD.
• - Caregivers and family members, including those who have lost loved ones to these diseases.

This broadened approach to participation highlights a collective dedication to accelerating research previously hindered by a lack of comprehensive data. Every shared story contributes essential insights that help delineate the multifaceted nature of these illnesses, affirming the foundation's ultimate goal: to facilitate breakthroughs that lead to a cure for pulmonary fibrosis and interstitial lung disease.

For anyone looking to enroll or gain more information, the PFF encourages visits to pffregistry.org.

About the Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation is deeply committed to propelling research initiatives, empowering affected communities, and enhancing care standards for individuals living with pulmonary fibrosis. The foundation's mission extends beyond immediate care, aiming for a future where pulmonary fibrosis is no longer a life-threatening condition. Acknowledged for its transparency and effectiveness, the PFF has received high ratings from Charity Navigator, is accredited by the Better Business Bureau Wise Giving Alliance, and has secured a Platinum Seal of Transparency from Guidestar. More information about the PFF's initiatives can be found at pulmonaryfibrosis.org or by calling 844.TalkPFF (844.825.5733).